Department of Pediatrics, Hat Yai Medical Education Center, Hat Yai Hospital, Hat Yai, Songkhla, Thailand.
Am J Perinatol. 2018 Dec;35(14):1366-1375. doi: 10.1055/s-0038-1660462. Epub 2018 Jun 19.
Persistent pulmonary hypertension of the newborn (PPHN) is a complication of several respiratory diseases characterized by an elevation in pulmonary vascular resistance with resultant right-to-left shunting of blood and severe hypoxemia in the neonatal period. PPHN carries a high rate of morbidity and mortality, particularly in limited-resource settings (low-income and/or developing country). Echocardiography remains the gold standard for diagnosis of PPHN. Modern therapies such as inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators agents can reduce the mortality rate of PPHN. Unfortunately, echocardiography and the use of these modern therapies are often difficult for a medical institution to provide for patients in developing countries, even when a timely diagnosis of PPHN has been made. In this review, the practical challenges of timely diagnosis of PPHN and efficient use of available treatment options faced by pediatricians or neonatologists in limited-resource settings are discussed.
新生儿持续性肺动脉高压(PPHN)是多种呼吸系统疾病的并发症,其特征是肺血管阻力升高,导致血液从右向左分流,并在新生儿期出现严重的低氧血症。PPHN 的发病率和死亡率都很高,特别是在资源有限的环境中(低收入和/或发展中国家)。超声心动图仍然是 PPHN 诊断的金标准。吸入一氧化氮、高频振荡通气、体外膜氧合和/或其他肺血管扩张剂等现代疗法可以降低 PPHN 的死亡率。不幸的是,即使及时诊断出 PPHN,对于发展中国家的医疗机构来说,提供超声心动图和使用这些现代疗法往往也很困难。在这篇综述中,讨论了资源有限环境中的儿科医生或新生儿科医生在及时诊断 PPHN 和有效利用现有治疗方案方面面临的实际挑战。